Treatment of autoimmune diseases.
Therapeutic applications
- <h3><span class="text-deep-blue">Automatisierte Peritonealdialyse (APD)</span></h3>
- <h3><span class="text-deep-blue">Automatisierte Peritonealdialyse (APD)</span></h3>
- <h3><span class="text-deep-blue">Automatisierte Peritonealdialyse (APD)</span></h3>
- <h3><span class="text-deep-blue">Automatisierte Peritonealdialyse (APD)</span></h3>
After transplantation, acute or chronic antibody-mediated rejection can lead to organ loss. In many cases where such rejection reactions do not respond sufficiently to drugs, they may be rapidly and effectively interrupted by an apheresis procedure like therapeutic plasma exchange or immunoadsorption.1 In patients with an increased risk of transplant rejection, a preventive removal of antibodies against histocompatibility or blood group antigens using immunoadsorption is a proven established modality.2‑5
Indications to be considered for therapeutic apheresis treatments (based on individualized decision making) include:25,26
- Nephritis associated with infections or systemic disorders
- Primary or idiopathic membranous nephropathy6
- Rapidly progressive glomerulonephritis (RPGN)7
- Goodpasture’s syndrome7
- Recurrent focal segmental glomerulosclerosis (FSGS)8‑10
GLOBAFFINEffective broad-spectrum immunoadsorption
To decrease the high plasma levels of IgG that play a major role in many neurological diseases, patients can be treated either through the use of immunoadsorption techniques that selectively reduce IgG or with plasma exchange, which is a rather unselective method.
The use of therapeutic plasma exchange or immunoadsorption to remove antibodies can be considered for intervention in the acute exacerbation of autoimmune diseases and in patients who do not respond, or only weakly respond, to immunosuppressive therapy.19,21
In addition to the mentioned indications, therapeutic apheresis can also be applied to:
- Chronic inflammatory demyelinating polyneuropathy (CIDP) 22,23,25
- Lambert-Eaton syndrome 24,25
GLOBAFFINEffective broad-spectrum immunoadsorption
Medical information
Therapeutic apheresis in COVID-19
PDF, 84 KBRelated content
1 Böhmig GA et al. Am J Transplant 2007; 7:117-121
2 Schwaiger E et al. Nephrol Dial Transplant 2016; 31(8):1342-1351
3 Morath C et al. Transpl Int 2012; 25(5):506-517
4 Bartel G et al. Am J Transplant 2010; 10(9):2033-2042
5 Thölking G et al. PLoS One 2015; 10(6):e0131465
6 Hamilton P et al. J Clin Apher 2022; 37:40-53
7 Biesenbach P et al. PLoS One 2014; 9(7):e103568
8 Dantal J et al. N Engl J Med 1994; 330(1):7-14
9 Moriconi L et al. Ren Fail 2001; 23(3-4):533-541
10 Meyer TN et al. Transpl Int 2007; 20(12):1066-1071
11 Eming R et al. Dermatology 2006; 212(2):177-187
12 Hübner F et al. J Dtsch Dermatol Ges 2018; 16(9):1109-1118
13 Meyersburg D et al. Ther Apher Dial 2012; 16(4):311-320
14 Eming R et al. Autoimmunity 2006; 39(7):609-616
15 Kridin K et al. Dermatol Clin 2019; 37:215–228
16 Seta T et al. Clin Neurol Neurosurg 2005; 107:491-496
17 Benny WB et al. Transfusion 1999; 39:682-687
18 Dogan Onugoren M et al. Neurol Neuroimmunol Neuroinflamm 2016; 26; 3(2):e207
19 Dorst J et al. EClinicalMedicine 2019; 16:98-106
20 Hempel P et al. Ther Apher Dial 2016; 20(5):523-529
21 Dorst J et al. J Mult Scler (Foster City) 2016; 3:178
22 Dorst J et al. J Neurol 2018; 265:2906-2915
23 Rech J et al. Ther Apher Dial. 2008;12(3):205-208
24 Baggi F et al. J Neuroimmunol. 2008;201-202:104-110
25 Padmanabhan A et al. J Clin Apher 2019; 34:171-354
26 Chen YY et al. Ren Fail 2022; 44:842-857
27 Richtlinie Methoden vertragsärztliche Versorgung; BAnz AT 30.03.2021 B4
28 Heigl F et al. Atheroscler Suppl 2019;40:23-29
29 Kosmadakis G Int J Artif Organs 2022;45(5):445-454
30 Mehdi et al. Nephrol Dial Transplant 2019;34(S1):i234– i235
31 Pithova et al. Poster presented at the DFSG congress; 2017 Sept 8-10; Porto, Portugal
32 Soltész et al. Orv Hetil 2021;162(10):375–382
33 Weinmann K et al. Biomolecules. 2018; 8(4):133
34 Staudt et al. Clin Pharmacol Ther. 2010; 87(4):452-458
35 Dandel M et al. Eur J Heart Fail. 2012; 14(12):1374-1388